India and China Could Be On The Brink Of A Biosimilars Takeoff, Says One Biotech CEO
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Asia's giants - India and China - could see a Big Bang-like explosion of biotech- and biosimilar-focused start-ups given the right conditions over the next decade, including an infusion of capital from the West, according to the head of an Indian biopharmaceutical firm
You may also be interested in...
Divi's Gears Up For A Biosimilars Play, Move Comes At The Back Of Demand From Existing Clients
HYDERABAD, India - Years of relationship with large multinational companies has prompted Divi's Labs - one of India's largest contract manufacturers for pharmaceutical raw materials or bulk drugs - to explore a presence in the biosimilars manufacturing space
Divi's Gears Up For A Biosimilars Play, Move Comes At The Back Of Demand From Existing Clients
HYDERABAD, India - Years of relationship with large multinational companies has prompted Divi's Labs - one of India's largest contract manufacturers for pharmaceutical raw materials or bulk drugs - to explore a presence in the biosimilars manufacturing space
Sanofi-Aventis Sees India's Shantha As Global Hub For Its Biotech Plans
MUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India